TITLE

IMMUNITOR REPORTS INTERIM DATA FROM PHASE IIB IMM01 TRIAL

PUB. DATE
February 2011
SOURCE
Worldwide Biotech;Feb2011, Vol. 23 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a study published by Immunitor, titled "Adjunct Oral Immunotherapy in Patients With Re-Treated, Multidrug-Resistant or HIV-Coinfected TB." The study covers the first half of the imm01 clinical trial of Immunitor's V5 immunomodulator product for the treatment of tuberculosis. Led by Olga Arjanova, the study aims to compare the effects of V5 immunotherapy against placebo for treatment of refractory tuberculosis.
ACCESSION #
57671635

 

Related Articles

  • Immunotherapy of Crohn's disease. Montfrans, C. Van; Camoglio, L.; Deventer, S. J. H. Van // Mediators of Inflammation;Jun98, Vol. 7 Issue 3, p149 

    ALTHOUGH the initiating events of Crohn's disease are unknown, models of experimental colitis have provided new insights in the immunologically mediated pathways of mucosal inflammation. In Crohn's disease activated mucosal T lymphocytes produce proinflammatory cytokines within the mucosal...

  • Pre-priming: a novel approach to DNA-based vaccination and immunomodulation. Kobayashi, Hiroko; Horner, Anthomy A.; Martin-Orozco, Elena; Raz, Eyal // Springer Seminars in Immunopathology;2000, Vol. 22 Issue 1/2, p85 

    Provides insight into the adjuvant and immunomodulatory capacity of immunostimulatory DNA sequence and oligodeoxynucleotides to prevent and treat allergic and infectious diseases. Activation of the innate immune system; Promotion of B cell proliferation; Stabilization of cell-cell interactions.

  • adjuvant:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p11 

    The article presents an encyclopedia entry about adjuvant. Adjuvant is characterized as something that improves medical treatment effectiveness. It also refers to a substance that either increase or decrease the effect of a drug ingredient. In the field of immunology, adjuvant is a substance...

  • Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S-28436: Efficacy... Buates, Sureemas; Matlashewski, Greg // Journal of Infectious Diseases;6/1/99, Vol. 179 Issue 6, p1485 

    Studies the efficacy of the immunomodulators imiquimod and S-28463 in the treatment of experimental leishmaniasis. Measurement of nitric oxide (NO) production and inhibition of NO synthesis with N[sup G]-monomeethyl-L-arginine; Analysis of activated signal transducer and activator of...

  • Risk-adaptive use of plerixafor effective and saves costs.  // PharmacoEconomics & Outcomes News;2/4/2012, Issue 646, p9 

    The article discusses a research study which investigated the efficacy and cost-benefit of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization, published in the January 2012 issue of the journal "Transfusion."

  • End of the line for tuberculosis "therapy"  // Bulletin of the World Health Organization;1999, Vol. 77 Issue 9, p780 

    Focuses on the treatment for tuberculosis. Diagnosis of pulmonary tuberculosis; Effectiveness of drugs for the treatment of tuberculosis patients; Efforts to improve prevention and treatment of the disease.

  • Inmunoterapia en Am�rica Latina. Del pasado al futuro. E. Baena Cagnani, Carlos; F. Lockey, Richard; Passalacqua, Giovanni; Walter Canonica, G. // Revista Alergia de Mexico;ene/feb2008, Vol. 55 Issue 1, p33 

    In Latin America, allergic diseases have a very high prevalence, comparable to that of many other countries of the world, and that prevalence is constantly increasing. Within the region, the number of allergy specialists is quite high, although allergy is not recognized as a full specialty in...

  • Immunological mechanisms in specific immunotherapy. Schmidt-Weber, Carsten B.; Blaser, Kurt // Springer Seminars in Immunopathology;Feb2004, Vol. 25 Issue 3/4, p377 

    Specific immunotherapy (SIT) represents the only curative treatment of allergy and is, therefore, of particular interest for immunological and pharmacological research. The current understanding of immunological mechanisms underlying SIT focuses on regulatory T cells (T regs), which balance Th1...

  • Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis. Mathur, Murli L. // Current Respiratory Medicine Reviews;2006, Vol. 2 Issue 2, p183 

    Mycobacterium w is a non-pathogenic, saprophytic, atypical mycobacterium with the ability to produce macrophage activating factors from lymphocytes of human patients. Prior immunization with heat-killed suspension of Mycobacterium w shows protection against sub-lethal infection with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics